Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Vertero Therapeutics

Request full access

Clinical-stage CNS bio-pharmaceutical company focused on small molecule therapies

Woburn, United StatesFounded 2016Biotech & Life Sciences

About Vertero Therapeutics

Axial Therapeutics, a clinical-stage biopharmaceutical company, was established in 2016 to concentrate on the connection between the human gut microbiome and neurological diseases. The company's scientific foundation is built upon the research of its co-founder, Dr. Sarkis Mazmanian, a professor at the California Institute of Technology (Caltech) whose work has explored the gut-brain axis and its implications for central nervous system (CNS) disorders. Dr. Mazmanian's extensive background in microbiology and immunology, particularly his research into how gut bacteria can influence health and disease, provides the scientific underpinning for the company's therapeutic approach.

Axial Therapeutics is developing a pipeline of small molecule therapies designed to address the neurological symptoms of conditions like Parkinson's disease (PD) and Autism Spectrum Disorder (ASD). The company's strategy focuses on identifying and targeting specific bacterial metabolites originating in the gut that are believed to contribute to disease pathology. Rather than using live biotherapeutics, Axial's approach is to develop orally-administered small molecules that can remove these harmful metabolites from the gut before they enter the bloodstream and impact the brain. This business model is centered on the traditional biopharmaceutical pathway of drug discovery, clinical development, and eventual commercialization of approved therapies. Its primary clients are patients suffering from these neurological disorders, with the products intended to be prescribed by healthcare professionals.

The company's lead product candidate, AB-2004, is a gut-targeted, molecular therapy being investigated for its potential to reduce irritability and anxiety in children with Autism Spectrum Disorder. AB-2004 is designed to selectively absorb certain gut-derived metabolites that are thought to cross the blood-brain barrier and affect brain function. The key differentiator for this product is its focus on the gastrointestinal system to treat neurological symptoms, potentially offering a safer profile by minimizing systemic exposure. In 2022, Axial completed a Phase 2b clinical trial for AB-2004 in adolescents with ASD. Another significant milestone was the completion of a Series C financing round in 2021, which raised $37.25 million to advance its clinical programs for both ASD and Parkinson's disease.

Source: Dealroom company data

At a glance

Status
Operational
Employees
12
Open positions
None listed
Dealroom signal
88.7/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Drug Development, Neurology, Microbiome, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Oct 2021 $37M $149M One Ventures · Corundum Systems Biology · UTokyo Innovation Platform · Seventure Partners —
SERIES BOther financing Jun 2019 $10M $40M Taiho Ventures —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Vertero Therapeutics website traffic

Latest recorded traffic for Vertero Therapeutics is 670 monthly website visits, down 66.5% over the last three months. Vertero Therapeutics's team grew 20% over the past year.

Latest monthly visits670 3-month web change-66.5% 1-year team growth+20%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Vertero Therapeutics in the Woburn ecosystem

Live from Dealroom

The Vertero Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Longwood Fund
  • Domain Associates
  • Kairos Ventures
  • Seventure Partners
  • Taiho Ventures

Series B and later5 investors entered at this stage

  • UTokyo Innovation Platform
  • One Ventures
  • Corundum Systems Biology
  • Taiho Pharma
  • Autism Impact Fund

Other known investors1 additional known investor

  • Caltech, California Institute of Technology
Team profiled 16 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States75%
🇦🇺 Australia16.7%
🇧🇪 Belgium8.3%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Vertero Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Vertero Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.